Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development
Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development
Tuesday, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) announced two tools to streamline the drug development process for pharmaceutical and biotech companies.
周二，Ginkgo Bioworks Holdings, Inc.（纽约证券交易所代码：DNA）宣布了两种工具，用于简化制药和生物技术公司的药物开发流程。
Building on its partnership with Alphabet Inc's (NASDAQ:GOOG) (NASDAQ:GOOGL) Google Cloud, Ginkgo introduced a protein large language model (LLM) and a model API, both designed to accelerate medicine development by leveraging AI and proprietary biological data.
在与Alphabet Inc（纳斯达克股票代码：GOOG）（纳斯达克股票代码：GOOG）谷歌云的合作基础上，Ginkgo推出了蛋白质大语言模型（LLM）和模型API，两者都旨在通过利用人工智能和专有生物数据来加速药物开发。
These offerings aim to simplify and enhance how researchers and companies discover new therapeutics.
这些产品旨在简化和增强研究人员和公司发现新疗法的方式。
Researchers at Google DeepMind have developed AlphaFold 3, an new artificial intelligence (AI) model.
谷歌DeepMind的研究人员开发了AlphaFold 3，这是一种新的人工智能（AI）模型。
AlphaFold 3 can predict the structure and interactions of biological molecules. This includes proteins, DNA RNA, and small molecules that could function as drugs.
AlphaFold 3 可以预测生物分子的结构和相互作用。这包括蛋白质、DNA RNA和可以用作药物的小分子。
The new protein LLM, developed in collaboration with Google Cloud Consulting and built on Vertex AI, offers powerful insights derived from Ginkgo's private data to individual researchers and enterprise companies.
新的蛋白质lLm是与谷歌云咨询公司合作开发的，建立在Vertex AI基础上，为个人研究人员和企业公司提供了从Ginkgo的私人数据中得出的强大见解。
The model can help identify new therapeutic targets by analyzing protein structures and interactions, speeding up the discovery and development of life-saving medicines.
该模型可以通过分析蛋白质结构和相互作用来帮助识别新的治疗靶标，从而加快救生药物的发现和开发。
This tool is expected to revolutionize drug development pipelines, optimizing the process from lead identification to final approval.
该工具有望彻底改变药物研发渠道，优化从线索识别到最终批准的流程。
In addition to the LLM, Ginkgo has launched its model API, an accessible and affordable tool aimed at providing machine learning scientists with AI models trained on Ginkgo's proprietary protein and DNA datasets.
除lLm外，Ginkgo还推出了其模型API，这是一种易于使用且价格合理的工具，旨在为机器学习科学家提供基于银杏专有蛋白质和DNA数据集训练的人工智能模型。
This API is available on Ginkgo's website, with plans for enterprise access through Google Cloud's Vertex AI Model Garden.
该API可在Ginkgo的网站上获得，并计划通过谷歌云的Vertex AI模型花园进行企业访问。
The API enables users to generate insights through advanced methods like masked language modeling and embedding calculations.
该 API 使用户能够通过掩码语言建模和嵌入计算等高级方法生成见解。
Ankit Gupta highlighted that predictions on protein sequences could be obtained for as little as $0.18 per million tokens, allowing researchers to scale their experiments without incurring high costs.
Ankit Gupta强调说，对蛋白质序列的预测可以以低至每百万个代币0.18美元的价格获得，这使研究人员能够在不产生高成本的情况下扩大实验规模。
Ginkgo plans to release more models over the next year, broadening the API's capabilities and expanding its suite of tools to tackle complex drug discovery, synthetic biology, and genomics challenges.
Ginkgo计划在明年发布更多模型，扩大API的能力并扩展其工具套件，以应对复杂的药物发现、合成生物学和基因组学挑战。
Price Action: DNA stock is up 11.60% at $6.95 at the last check on Tuesday.
价格走势：在周二的最后一次检查中，DNA股票上涨了11.60％，至6.95美元。
- Amazon's Leaner Structure and AI Chip Partnership with Intel Could Boost Growth: BofA Analyst.
- 美国银行分析师：亚马逊的精简结构和与英特尔的人工智能芯片合作伙伴关系可以促进增长。
Photo via Shutterstock
照片来自 Shutterstock